Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleINFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA

Anti-Inflammatory Effects of LJP 1586 [Z-3-Fluoro-2-(4-methoxybenzyl)allylamine Hydrochloride], an Amine-Based Inhibitor of Semicarbazide-Sensitive Amine Oxidase Activity

Anne M. O'Rourke, Eric Y. Wang, Andrew Miller, Erika M. Podar, Kelly Scheyhing, Li Huang, Christina Kessler, Hongfeng Gao, Huong-Thu Ton-Nu, Mary T. MacDonald, David S. Jones and Matthew D. Linnik
Journal of Pharmacology and Experimental Therapeutics February 2008, 324 (2) 867-875; DOI: https://doi.org/10.1124/jpet.107.131672
Anne M. O'Rourke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Y. Wang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Miller
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erika M. Podar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelly Scheyhing
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Li Huang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christina Kessler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hongfeng Gao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Huong-Thu Ton-Nu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary T. MacDonald
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David S. Jones
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew D. Linnik
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Semicarbazide-sensitive amine oxidase (SSAO, amine oxidase, copper-containing 3, and vascular adhesion protein-1) is a copper-containing enzyme that catalyzes the oxidative deamination of primary amines to an aldehyde, ammonia, and hydrogen peroxide. SSAO is also involved in leukocyte migration to sites of inflammation, and the enzymatic activity of SSAO is essential to this role. Thus, inhibition of SSAO enzyme activity represents a target for the development of small molecule anti-inflammatory compounds. Here, we have characterized the novel SSAO inhibitor, Z-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride (LJP 1586), and assessed its anti-inflammatory activity. LJP 1586 is a potent inhibitor of rodent and human SSAO activity, with IC50 values between 4 and 43 nM. The selectivity of LJP 1586 was confirmed with a broad panel of receptors and enzymes that included the monoamine oxidases A and B. Oral administration of LJP 1586 resulted in complete inhibition of rat lung SSAO, with an ED50 between 0.1 and 1 mg/kg, and a pharmacodynamic half-life of greater than 24 h. In a mouse model of inflammatory leukocyte trafficking oral dosing with LJP 1586 resulted in significant dose-dependent inhibition of neutrophil accumulation, with an effect comparable to that of anti-leukocyte function-associated antigen-1 antibody. In a rat model of LPS-induced lung inflammation, administration of 10 mg/kg LJP 1586 resulted in a 55% significant reduction in transmigrated cells recovered by bronchoalveolar lavage. The results demonstrate that a selective, orally active small molecule inhibitor of SSAO is an effective anti-inflammatory compound in vivo and provide further support for SSAO as a therapeutic anti-inflammatory target.

Footnotes

  • Parts of this article were previously presented in poster form: O'Rourke A, Miller A, Podar E, Scheyhing K, Huang L, Jones D, MacDonald M, Ton-Nu H, Wang E, and Linnik M (2006) Small molecule inhibitors of SSAO/AOC3 for therapy of inflammatory diseases, in Annual Meeting of the American College of Rheumatology; 2006 Nov 10–15; San Diego, CA. American College of Rheumatology, Atlanta, GA.

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

  • doi:10.1124/jpet.107.131672.

  • ABBREVIATIONS: SSAO, semicarbazide-sensitive amine oxidase; VAP-1, vascular adhesion protein-1; LPS, lipopolysaccharide; MAO, monoamine oxidase; DAO, diamine oxidase; ANOVA, analysis of variance; COX; cyclooxygenase; LJP 1586, Z-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride; TPQ, topaquinone; LJP 1207, N′(2-phenyl-allyl)-hydrazine hydrochloride; CHO, Chinese hamster ovary; BAL, bronchoalveolar lavage; PBS, phosphate-buffered saline; PK, pharmacokinetics; UC, umbilical cord(s); AOC, amine oxidase, copper-containing; FAD, flavin adenine dinucleotide; LFA, leukocyte function-associated antigen.

    • Received September 13, 2007.
    • Accepted November 8, 2007.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 387 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 387, Issue 1
1 Oct 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Anti-Inflammatory Effects of LJP 1586 [Z-3-Fluoro-2-(4-methoxybenzyl)allylamine Hydrochloride], an Amine-Based Inhibitor of Semicarbazide-Sensitive Amine Oxidase Activity
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleINFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA

Anti-Inflammatory Effects of LJP 1586 [Z-3-Fluoro-2-(4-methoxybenzyl)allylamine Hydrochloride], an Amine-Based Inhibitor of Semicarbazide-Sensitive Amine Oxidase Activity

Anne M. O'Rourke, Eric Y. Wang, Andrew Miller, Erika M. Podar, Kelly Scheyhing, Li Huang, Christina Kessler, Hongfeng Gao, Huong-Thu Ton-Nu, Mary T. MacDonald, David S. Jones and Matthew D. Linnik
Journal of Pharmacology and Experimental Therapeutics February 1, 2008, 324 (2) 867-875; DOI: https://doi.org/10.1124/jpet.107.131672

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleINFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA

Anti-Inflammatory Effects of LJP 1586 [Z-3-Fluoro-2-(4-methoxybenzyl)allylamine Hydrochloride], an Amine-Based Inhibitor of Semicarbazide-Sensitive Amine Oxidase Activity

Anne M. O'Rourke, Eric Y. Wang, Andrew Miller, Erika M. Podar, Kelly Scheyhing, Li Huang, Christina Kessler, Hongfeng Gao, Huong-Thu Ton-Nu, Mary T. MacDonald, David S. Jones and Matthew D. Linnik
Journal of Pharmacology and Experimental Therapeutics February 1, 2008, 324 (2) 867-875; DOI: https://doi.org/10.1124/jpet.107.131672
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • PAR2 inhibition reduces neuroinflammation
  • First-in-Human Phase 1 Trial with KPL-404
  • CCR6 Selective Antagonist in Homeostasis and Inflammation
Show more Inflammation, Immunopharmacology, and Asthma

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics